Video

Cell Therapies May Help Overcome Drug Resistance in Patients With Mantle Cell Lymphoma

Author(s):

Dr. Michael Wang
Conference|ASCO Annual Meeting

Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.

Drug resistance is one major roadblock in cancer researchers’ way of improving patient outcomes in mantle cell lymphoma (MCL) treatment, according to Dr. Luhua (Michael) Wang.

However, promising developments in the treatment of MCL and other B-cell lymphomas could help patients overcome drug resistance and live longer lives.

“To overcome drug resistance, we’ve had three major technology achievements in the past few years. In the past, we always used chemotherapy,” said Wang, who is a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, explaining that the rapid advancements included targeted therapies, immunotherapies and cell therapies.

At the 2019 American Society of Clinical Oncology Annual (ASCO) Meeting, Wang discussed study findings and the technological advances in B-cell lymphoma treatment space that provide hope for patients with MCL of overcoming drug resistance and potentially live longer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Related Content
From left: KATHLEEN COUGHLIN, M.S.N., ANP-BC, BMTCN, and ANTONIA MALONEY, B.S.N., RN, OCN
April 24th 2025

The Fearless Patient Advocate

Antonia Maloney, BSN, RN, OSN
Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation: © stock.adobe.com.
April 19th 2025

Illuminating Compassion in Cancer Care

Mike Hennessy Jr.
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of man holding stomach.
April 6th 2025

FDA Grants HLX22 Orphan Drug Designation for Gastric Cancer

Spencer Feldman
FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.